Strong demand enabling the contemplated size of the transaction to be significantly increased from 11 M€ to 15.6 M€ (+42%)
Major support from French and international shareholders and investors
Additional resources to finance the development of the product portfolio based on BEPO® technology combined with already approved and widely used active ingredients
Increased financial flexibility enabling the Company to achieve its strategic objectives and cover its working capital requirements until the second half of 2022 ; at this time MedinCell should already be receiving royalty revenues from the sale of the first products based on the BEPO® technology
Contacts
MedinCell announces the great success of its capital increase and raises 15.6 M€
June 16, 2020